Quantbot Technologies’s C4 Therapeutics CCCC Stock Holding History

Quantbot Technologies’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.3K	Buy	+20,827	New	+$71.2K	﹤0.01%	1477
2024 Q2	–	Sell	-10,300	Closed	-$84.2K	–	1484
2024 Q1	$84.2K	Buy	+10,300	New	+$79.8K	﹤0.01%	1234
2023 Q4	–	Sell	-5,796	Closed	-$10.8K	–	1608
2023 Q3	$10.8K	Sell	5,796 -9,523	-62%	-$29K	﹤0.01%	1404
2023 Q2	$42.1K	Buy	15,319 +11,800	+335%	+$37.9K	﹤0.01%	1340
2023 Q1	$11.1K	Sell	3,519 -1,574	-31%	-$9.27K	﹤0.01%	1407
2022 Q4	$30K	Buy	+5,093	New	+$42.2K	﹤0.01%	1389
2022 Q1	–	Sell	-1,700	Closed	-$54K	–	1674
2021 Q4	$54K	Sell	1,700 -2,000	-54%	-$79.1K	﹤0.01%	1004
2021 Q3	$165K	Buy	+3,700	New	+$158K	0.01%	848

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quantbot Technologies's CCCC Position: Q2 2026 in Review

Quantbot Technologies opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 20,827 shares worth $97.3K. The stake represents ﹤0.01% of the portfolio and ranks #1477 among its holdings. This is a return to the name: Quantbot Technologies previously reported a position in CCCC as recently as Q1 2024.

Quantbot Technologies first reported a position in CCCC in Q3 2021 and has held it in 8 quarters since. The position peaked at $165K in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Quantbot Technologies held 20,827 shares of C4 Therapeutics worth $97.3K as of Q2 2026.
C4 Therapeutics was a new Quantbot Technologies position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Quantbot Technologies's portfolio in Q2 2026, its #1477 holding.
Quantbot Technologies first reported a position in C4 Therapeutics in Q3 2021 and has held it in 8 quarters since.
Quantbot Technologies's C4 Therapeutics position peaked at $165K in Q3 2021.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Quantbot Technologies's 13F filing for Q2 2026, filed 12 Aug 2026.